Tesofensine
NS2330 · tesofensine oral
Oral triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) studied for obesity. Not a peptide. Not a GLP-1. Not reconstitution math. Sometimes discussed next to incretins as a plateau adjunct — that is pharmacology folklore, not a labeled stack.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight5/10
Human obesity trials exist for the monoamine mechanism. Haircut: not an FDA obesity pen; cardiovascular/psychiatric class cautions; not a peptide.
Compound card
- Sequence
- Small-molecule triple monoamine reuptake inhibitor (NS2330)
- Class
- Oral obesity research / regional medicine class (not a peptide)
- Formula
- Small molecule (NS2330)
- Status
- Not FDA-approved · research use
How it works
Tesofensine (NS2330) is an oral inhibitor of dopamine, norepinephrine, and serotonin reuptake studied for weight loss. It is not a GLP-1, not a peptide, and not something you put in the reconstitution calculator.
People search it next to incretins as a “plateau” adjunct. That is a pharmacology conversation, not a labeled stack and not a reason this site invents a combined protocol.
Source: Published tesofensine obesity trial literature; confirm jurisdiction and prescription status
Research Use Cases
- ✓Weight (oral non-peptide): Moderate
- ✓Peptide reconstitution: Low
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Oral programs | Program / jurisdiction dependent | Once daily oral | Published trial bands exist in the literature. This leaf will not paste a gray-market capsule chart as medical advice. |
Administration
Timeline
Who it is for
Weight (oral non-peptide)
ModerateReal trial history. Clinician and jurisdiction decide legality and monitoring.
Peptide reconstitution
LowWrong category entirely.
Safety & Considerations
Central monoamine agent. Heart rate, blood pressure, mood, and sleep can move. Not for casual polypharmacy next to stimulants or other serotonergic drugs without a clinician. Not a peptide burn/PIP story.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Not a peptide. Calculator math does not apply.
- Not FDA-approved as a US obesity drug on this leaf’s default reading — jurisdiction matters.
- Monoamine agents carry cardiovascular and psychiatric monitoring stories. This page is not a prescribing guide.
- Stacking folklore with tirzepatide is not a labeled protocol on this site.
Verdict
Tesofensine is an oral monoamine reuptake obesity molecule, not a peptide and not a GLP-1. Use it as an identity leaf. Do not invent a reconstitution chart or a labeled incretin stack.
Interactions & Contraindications
Central monoamine agent. Heart rate, blood pressure, mood, and sleep can move. Not for casual polypharmacy next to stimulants or other serotonergic drugs without a clinician. Not a peptide burn/PIP story.
Appears in goal guides
Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.
Frequently Asked Questions
Is tesofensine a peptide?▼
Can I mix it with tirzepatide?▼
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code